SHERWIN STEPHEN A 4

4 · NEUROCRINE BIOSCIENCES INC · Filed May 30, 2024

Form 4

Period: 2024-05-29

Director

Transactions

Exercise/Conversion
Common Stock
2024-05-29$42.76/sh+25,000$1,069,000→ 51,504 total
Exercise/Conversion
Common Stock
2024-05-29$47.89/sh+15,000$718,350→ 41,504 total
Sale
Common Stock
2024-05-29$133.47/sh−15,000$2,002,010→ 26,504 total
Sale
Common Stock
2024-05-29$133.46/sh−25,000$3,336,555→ 26,504 total
Exercise/Conversion
Non-Qualified Stock Option
2024-05-29−25,000→ 0 total
Exercise: $42.76Exp: 2025-05-28→ Common Stock (25,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option
2024-05-29−15,000→ 0 total
Exercise: $47.89Exp: 2026-05-20→ Common Stock (15,000 underlying)

Footnotes (5)

[F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2024.
[F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.22 to $136.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.00 to $136.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.
[F5]The option was granted May 20, 2016 and vested in 12 equal monthly installments beginning June 20, 2016. These options will expire ten years from the date of grant on May 20, 2026.

Documents

1 file